|
|
 | | | |
- close
- close
- close
- close
AEterna Zentaris (AEZS) |
QUOTE AND NEWS
Marketwire
May 18
Comment
NEW YORK, NY -- (Marketwire) -- 05/18/12 -- The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry of mergers & acquisitions activity and a growing
Benzinga
May 16
Comment
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced today that it has received a notice from The NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days, and, therefore, was not in...
StreetInsider.com
May 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Aeterna+%28AEZS%29%2C+Keryx+%28KERX%29+Terminate+Perifosine+License+Agreement+in+North+America/7407206.html for the full story.
Marketwire
May 3
Comment
NEW YORK, NY -- (Marketwire) -- 05/03/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will
StreetInsider.com
Apr 3
Comment
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
Vringo, Inc. (AMEX: VRNG) high of $4.05. Shares began ripping higher Monday following the late-Friday filing of...
MarketWatch
Apr 2
Comment
Shares of Keryx Pharmaceuticals and partner AEterna Zentaris Inc. imploded Monday morning on disappointing results from a key Phase III clinical trial for their drug candidate perifosine in the treatment of advanced colorectal cancer. Keryx and...
FierceBiotech
Apr 2
Comment
Canada's Aeterna Zentaris ($AEZS) put out the word this morning that perifosine flamed out in a late-stage cancer study conducted by its partner Keryx Biopharmaceuticals ($KERX). The treatment failed to hit the primary endpoint laid out for a...
StreetInsider.com
Apr 2
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+Keryx+%28KERX%29+Says+KRX-0401+%2B+Xeloda+Did+Not+Meet+Primary+Endpoint+in+Phase+3%3B+AEterna+Zentaris+%28AEZS%29%2C+Keryx+Halted/7312402.html for the full story.
MarketWatch
Mar 16
Comment
Shares of partners Keryx Biopharmaceuticals and Canadian biotech group AEterna Zentaris were in play again Friday, ahead of the expected release of data from a key study for their oncology drug candidate perifosine. Shares of Keryx were up 12%...
Marketwire
Mar 12
Comment
NEW YORK, NY -- (Marketwire) -- 03/12/12 -- The biotechnology industry has been on an impressive run this year as companies -- both large and small -- show impressive growth. The iShares Nasdaq Biotechnology Index (IBB) Fund is outperforming the
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
